Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1990 1
1991 2
1992 3
1993 2
1994 5
1995 2
1996 5
1997 9
1998 12
1999 7
2000 5
2001 3
2002 1
2005 1
2006 2
2007 2
2008 2
2009 3
2010 1
2011 2
2012 2
2013 3
2014 3
2015 3
2016 4
2017 4
2018 2
2019 3
2020 3
2022 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

90 results

Results by year

Filters applied: . Clear all
Page 1
Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study.
Dimopoulos MA, Moreau P, Palumbo A, Joshua D, Pour L, Hájek R, Facon T, Ludwig H, Oriol A, Goldschmidt H, Rosiñol L, Straub J, Suvorov A, Araujo C, Rimashevskaya E, Pika T, Gaidano G, Weisel K, Goranova-Marinova V, Schwarer A, Minuk L, Masszi T, Karamanesht I, Offidani M, Hungria V, Spencer A, Orlowski RZ, Gillenwater HH, Mohamed N, Feng S, Chng WJ; ENDEAVOR Investigators. Dimopoulos MA, et al. Lancet Oncol. 2016 Jan;17(1):27-38. doi: 10.1016/S1470-2045(15)00464-7. Epub 2015 Dec 5. Lancet Oncol. 2016. PMID: 26671818 Free article. Clinical Trial.
Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial.
Dimopoulos MA, Gay F, Schjesvold F, Beksac M, Hajek R, Weisel KC, Goldschmidt H, Maisnar V, Moreau P, Min CK, Pluta A, Chng WJ, Kaiser M, Zweegman S, Mateos MV, Spencer A, Iida S, Morgan G, Suryanarayan K, Teng Z, Skacel T, Palumbo A, Dash AB, Gupta N, Labotka R, Rajkumar SV; TOURMALINE-MM3 study group. Dimopoulos MA, et al. Lancet. 2019 Jan 19;393(10168):253-264. doi: 10.1016/S0140-6736(18)33003-4. Epub 2018 Dec 10. Lancet. 2019. PMID: 30545780 Clinical Trial.
All-trans-retinoic acid, idarubicin, and IV arsenic trioxide as initial therapy in acute promyelocytic leukemia (APML4).
Iland HJ, Bradstock K, Supple SG, Catalano A, Collins M, Hertzberg M, Browett P, Grigg A, Firkin F, Hugman A, Reynolds J, Di Iulio J, Tiley C, Taylor K, Filshie R, Seldon M, Taper J, Szer J, Moore J, Bashford J, Seymour JF; Australasian Leukaemia and Lymphoma Group. Iland HJ, et al. Blood. 2012 Aug 23;120(8):1570-80; quiz 1752. doi: 10.1182/blood-2012-02-410746. Epub 2012 Jun 19. Blood. 2012. PMID: 22715121 Free article. Clinical Trial.
Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial.
Dimopoulos MA, Richardson PG, Bahlis NJ, Grosicki S, Cavo M, Beksaç M, Legieć W, Liberati AM, Goldschmidt H, Belch A, Magen H, Larocca A, Laubach JP, Petrucci MT, Reece D, White D, Mateos MV, Špička I, Lazaroiu M, Berdeja J, Kaufman JL, Jou YM, Ganetsky A, Popa McKiver M, Lonial S, Weisel K; ELOQUENT-1 investigators. Dimopoulos MA, et al. Lancet Haematol. 2022 Jun;9(6):e403-e414. doi: 10.1016/S2352-3026(22)00103-X. Epub 2022 May 9. Lancet Haematol. 2022. PMID: 35550060 Clinical Trial.
Bone marrow transplantation in leukemia.
Rowlings PA, Gale RP, Horowitz MM, Bortin MM. Rowlings PA, et al. J Hematother. 1994 Fall;3(3):235-8. doi: 10.1089/scd.1.1994.3.235. J Hematother. 1994. PMID: 7827872 Review.
'Real-world' Australian experience of pomalidomide for relapsed and refractory myeloma.
Scott A, Weber N, Tiley C, Taylor K, Taper J, Harrison S, Chan KL, Stark R, Lee C, Morris K, Ho PJ, Dodds A, Ramanathan S, Ramakrishna R, Watson AM, Auguston B, Kwok F, Quach H, Warburton P, Rowlings P, Mollee P. Scott A, et al. Among authors: rowlings p. Leuk Lymphoma. 2018 Jun;59(6):1514-1516. doi: 10.1080/10428194.2017.1387911. Epub 2017 Oct 12. Leuk Lymphoma. 2018. PMID: 29022836 No abstract available.
90 results